If you have been reading about Albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
=== FDA label expansion and marketing controversy === In January 2018, the U.S. Food and Drug Administration (FDA) expanded the label for Invega Sustenna to state that the drug "may delay time to arrest and/or incarceration" in patients with schizophrenia. The revised label was based on the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study, a Janssen‑sponsored, open‑label, 15‑month trial that enrolled 444 adults aged 18 to 65 who had been taken into custody at least twice in the previous two years, and at least once in the prior 90 days; about 60% had a concurrent substance use disorder and 14% were homeless. Participants were randomized to once‑monthly paliperidone palmitate or one of seven daily oral antipsychotics. The study, conducted between May 2010 and December 2013, found a significantly longer time to treatment failure—a composite measure that included arrest and/or incarceration, psychiatric hospitalization, treatment discontinuation because of safety or tolerability, treatment supplementation because of inadequate efficacy, need for increased psychiatric services to prevent hospitalization, and suicide—in the injectable group than in the oral antipsychotic group. The label expansion, which granted Janssen three additional years of market exclusivity for paliperidone palmitate, attracted significant criticism from mental health experts and the media.
=== Antimicrobial Platelets === Platelet-mimicking particles engineered with antimicrobial properties offer a novel approach to combating infections by targeting pathogens at injury sites, enhancing immune responses, and delivering antimicrobial agents directly to affected areas. While platelets are often recognized for their hemostatic role, more recent research focuses on their ability to fight infections by releasing antimicrobial molecules and through interactions with immune cells. Building on these properties, synthetic antimicrobial platelets can be an attractive targeted therapy for preventing and treating infections, particularly in trauma, surgery, and immunocompromised patients. An approach to developing antimicrobial platelet-like particles (PLPs) involves the integration of nanosilver— a material known for its potent antimicrobial activity. Recent findings have reported that nanosilver composite PNIPAM microgels incorporated into PLPs (Ag-PLPs) effectively inhibited bacterial growth while maintaining key platelet functions such as deformability and clot retraction.4 This balance is needed in order for antimicrobial synthetic platelets to induce wound healing as well as hemostasis, while keeping infection risk at minimum. Ag-PLPs, in a wound experimental model, not only increased clot retraction but also performance of healing, suggesting its regard as a "two-in-one therapy" for high-risk infection trauma patients.
Brassinosteroids (BRs) are a class of polyhydroxysteroids, the only example of steroid-based hormones in plants. Brassinosteroids control cell elongation and division, gravitropism, resistance to stress, and xylem differentiation. They inhibit root growth and leaf abscission. Brassinolide was the first brassinosteroid to be identified and was isolated from extracts of rapeseed (Brassica napus) pollen in 1979. Brassinosteroids are a class of steroidal phytohormones in plants that regulate numerous physiological processes. This plant hormone was identified by Mitchell et al. who extracted ingredients from Brassica pollen only to find that the extracted ingredients' main active component was Brassinolide. This finding meant the discovery of a new class of plant hormones called Brassinosteroids. These hormones act very similarly to animal steroidal hormones by promoting growth and development. In plants these steroidal hormones play an important role in cell elongation via BR signaling. The brassinosteroids receptor brassinosteroid insensitive 1 (BRI1) is the main receptor for this signaling pathway. This BRI1 receptor was found by Clouse et al. who made the discovery by inhibiting BR and comparing it to the wildtype in Arabidopsis. The BRI1 mutant displayed several problems associated with growth and development such as dwarfism, reduced cell elongation and other physical alterations. These findings mean that plants properly expressing brassinosteroids grow more than their mutant counterparts.
Sources: en.wikipedia.org
The branch extended to the Mezhdunarodnaya station in 2006; all work on the third station, Dorogomilovskaya (between Kiyevskaya and Delovoi Tsentr), has been postponed. The branch is planned for extension as far as the Savyolovskaya station, on the Serpukhovsko-Timiryazevskaya Line. On 5 March 2021, the company MTS announced the launch of the country's first pilot 5G network in Moscow.
== Function == GPX1 is ubiquitously expressed in many tissues, where it protects cells from oxidative stress. Within cells, it localizes to the cytoplasm and mitochondria. As a glutathione peroxidase, GPx1 functions in the detoxification of hydrogen peroxide, specifically by catalyzing the reduction of hydrogen peroxide to water. The glutathione peroxidase also catalyzes the reduction of other organic hydroperoxides, such as lipid peroxides, to the corresponding alcohols. GPx1 typically uses glutathione (GSH) as the reductant, but when glutathione synthetase (GSS) is, as in brain mitochondria, γ-glutamylcysteine can serve as the reductant instead. The protein encoded by this gene protects from CD95-induced apoptosis in cultured breast cancer cells and inhibits 5-lipoxygenase in blood cells, and its overexpression delays endothelial cell death and increases resistance to toxic challenges, especially oxidative stress. This protein is one of only a few proteins known in higher vertebrates to contain selenocysteine, which occurs at the active site of glutathione peroxidase and is coded by the nonsense (stop) codon TGA.
==== MeSH E05.393.661 – nucleic acid hybridization ==== MeSH E05.393.661.124 – branched dna signal amplification assay MeSH E05.393.661.250 – heteroduplex analysis MeSH E05.393.661.475 – in situ hybridization MeSH E05.393.661.475.350 – in situ hybridization, fluorescence MeSH E05.393.661.475.350.125 – chromosome painting MeSH E05.393.661.475.680 – primed in situ labeling MeSH E05.393.661.640 – oligonucleotide array sequence analysis
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.